- Home
- INSM vs FITB Comparison
INSM vs FITB Comparison
Compare INSM & FITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FITB
- Stock Information
- Founded
- INSM 1988
- FITB 1858
- Country
- INSM United States
- FITB United States
- Employees
- INSM N/A
- FITB N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FITB Major Banks
- Sector
- INSM Health Care
- FITB Finance
- Exchange
- INSM Nasdaq
- FITB Nasdaq
- Market Cap
- INSM 29.0B
- FITB 29.9B
- IPO Year
- INSM 2000
- FITB N/A
- Fundamental
- Price
- INSM $182.69
- FITB $42.10
- Analyst Decision
- INSM Strong Buy
- FITB Buy
- Analyst Count
- INSM 19
- FITB 16
- Target Price
- INSM $171.12
- FITB $49.94
- AVG Volume (30 Days)
- INSM 2.1M
- FITB 8.7M
- Earning Date
- INSM 10-30-2025
- FITB 10-17-2025
- Dividend Yield
- INSM N/A
- FITB 3.80%
- EPS Growth
- INSM N/A
- FITB 11.33
- EPS
- INSM N/A
- FITB 3.35
- Revenue
- INSM $447,022,000.00
- FITB $8,125,000,000.00
- Revenue This Year
- INSM $40.09
- FITB $15.99
- Revenue Next Year
- INSM $129.64
- FITB $27.84
- P/E Ratio
- INSM N/A
- FITB $12.58
- Revenue Growth
- INSM 30.34
- FITB 0.77
- 52 Week Low
- INSM $60.40
- FITB $32.25
- 52 Week High
- INSM $197.08
- FITB $49.07
- Technical
- Relative Strength Index (RSI)
- INSM 67.29
- FITB 46.48
- Support Level
- INSM $178.76
- FITB $41.43
- Resistance Level
- INSM $197.08
- FITB $42.75
- Average True Range (ATR)
- INSM 7.01
- FITB 1.06
- MACD
- INSM 1.60
- FITB 0.03
- Stochastic Oscillator
- INSM 65.96
- FITB 68.79
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About FITB Fifth Third Bancorp
Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $210 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.